Kyle W. Becker

1.9k total citations · 2 hit papers
17 papers, 1.5k citations indexed

About

Kyle W. Becker is a scholar working on Immunology, Molecular Biology and Oncology. According to data from OpenAlex, Kyle W. Becker has authored 17 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Immunology, 9 papers in Molecular Biology and 3 papers in Oncology. Recurrent topics in Kyle W. Becker's work include Immunotherapy and Immune Responses (8 papers), interferon and immune responses (7 papers) and Immune Response and Inflammation (5 papers). Kyle W. Becker is often cited by papers focused on Immunotherapy and Immune Responses (8 papers), interferon and immune responses (7 papers) and Immune Response and Inflammation (5 papers). Kyle W. Becker collaborates with scholars based in United States and China. Kyle W. Becker's co-authors include John T. Wilson, Eric P. Skaar, Daniel Shae, Plamen P. Christov, Sema Sevimli, Justin M. Balko, Mark C. Kelley, Dong Soo Yun, Abigail K. R. Lytton‐Jean and Manuel Ascano and has published in prestigious journals such as ACS Nano, Nature Nanotechnology and Biomaterials.

In The Last Decade

Kyle W. Becker

17 papers receiving 1.5k citations

Hit Papers

Endosomolytic polymersomes increase the activity of cycli... 2019 2026 2021 2023 2019 2024 100 200 300 400 500

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kyle W. Becker United States 15 939 612 367 236 226 17 1.5k
Yaomei Tian China 20 409 0.4× 831 1.4× 154 0.4× 154 0.7× 294 1.3× 36 1.5k
Songyin Huang China 19 169 0.2× 873 1.4× 193 0.5× 141 0.6× 189 0.8× 33 1.5k
Ernesto R. Soto United States 13 258 0.3× 521 0.9× 169 0.5× 81 0.3× 52 0.2× 31 1.3k
Barbara Jane Dillon United States 16 586 0.6× 425 0.7× 136 0.4× 921 3.9× 46 0.2× 24 1.6k
Kapil Khatri India 22 330 0.4× 687 1.1× 166 0.5× 96 0.4× 61 0.3× 47 1.5k
Zifu Zhong Belgium 16 412 0.4× 559 0.9× 183 0.5× 219 0.9× 129 0.6× 45 1.0k
Padma Malyala United States 15 654 0.7× 637 1.0× 86 0.2× 132 0.6× 67 0.3× 19 1.2k
Jie Liang China 13 261 0.3× 512 0.8× 401 1.1× 42 0.2× 101 0.4× 19 1.1k
Chunxi Zeng United States 15 355 0.4× 1.0k 1.6× 219 0.6× 215 0.9× 147 0.7× 26 1.4k

Countries citing papers authored by Kyle W. Becker

Since Specialization
Citations

This map shows the geographic impact of Kyle W. Becker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kyle W. Becker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kyle W. Becker more than expected).

Fields of papers citing papers by Kyle W. Becker

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kyle W. Becker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kyle W. Becker. The network helps show where Kyle W. Becker may publish in the future.

Co-authorship network of co-authors of Kyle W. Becker

This figure shows the co-authorship network connecting the top 25 collaborators of Kyle W. Becker. A scholar is included among the top collaborators of Kyle W. Becker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kyle W. Becker. Kyle W. Becker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Wang-Bishop, Lihong, Mohamed Wehbe, Jinming Yang, et al.. (2024). Nanoparticle Retinoic Acid-Inducible Gene I Agonist for Cancer Immunotherapy. ACS Nano. 18(18). 11631–11643. 13 indexed citations
2.
Baljon, Jessalyn J., Alexander J. Kwiatkowski, Amrendra Kumar, et al.. (2024). A Cancer Nanovaccine for Co-Delivery of Peptide Neoantigens and Optimized Combinations of STING and TLR4 Agonists. ACS Nano. 18(9). 6845–6862. 65 indexed citations breakdown →
3.
Becker, Kyle W., Kyle M. Garland, Karan Arora, et al.. (2022). A nanovaccine for enhancing cellular immunity via cytosolic co-delivery of antigen and polyIC RNA. Journal of Controlled Release. 345. 354–370. 26 indexed citations
4.
Jacobson, Max E., Kyle W. Becker, Olga Fedorova, et al.. (2020). Structural Optimization of Polymeric Carriers to Enhance the Immunostimulatory Activity of Molecularly Defined RIG-I Agonists. ACS Central Science. 6(11). 2008–2022. 29 indexed citations
5.
Wehbe, Mohamed, Lihong Wang-Bishop, Kyle W. Becker, et al.. (2020). Nanoparticle delivery improves the pharmacokinetic properties of cyclic dinucleotide STING agonists to open a therapeutic window for intravenous administration. Journal of Controlled Release. 330. 1118–1129. 92 indexed citations
6.
Shae, Daniel, Jessalyn J. Baljon, Mohamed Wehbe, et al.. (2020). Co-delivery of Peptide Neoantigens and Stimulator of Interferon Genes Agonists Enhances Response to Cancer Vaccines. ACS Nano. 14(8). 9904–9916. 132 indexed citations
7.
Shae, Daniel, Kyle W. Becker, Mohamed Wehbe, et al.. (2020). Amphiphilic Polyelectrolyte Graft Copolymers Enhance the Activity of Cyclic Dinucleotide STING Agonists. Advanced Healthcare Materials. 10(2). e2001056–e2001056. 16 indexed citations
8.
Shae, Daniel, Kyle W. Becker, Plamen P. Christov, et al.. (2019). Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy. Nature Nanotechnology. 14(3). 269–278. 540 indexed citations breakdown →
9.
Knight, Frances C., Pavlo Gilchuk, Amrendra Kumar, et al.. (2019). Mucosal Immunization with a pH-Responsive Nanoparticle Vaccine Induces Protective CD8+ Lung-Resident Memory T Cells. ACS Nano. 13(10). 10939–10960. 108 indexed citations
10.
Shae, Daniel, Jessalyn J. Baljon, Mohamed Wehbe, et al.. (2019). At the bench: Engineering the next generation of cancer vaccines. Journal of Leukocyte Biology. 108(4). 1435–1453. 25 indexed citations
11.
Qiu, Feng, Kyle W. Becker, Frances C. Knight, et al.. (2018). Poly(propylacrylic acid)-peptide nanoplexes as a platform for enhancing the immunogenicity of neoantigen cancer vaccines. Biomaterials. 182. 82–91. 76 indexed citations
12.
Jacobson, Max E., Lihong Wang-Bishop, Kyle W. Becker, & John T. Wilson. (2018). Delivery of 5′-triphosphate RNA with endosomolytic nanoparticles potently activates RIG-I to improve cancer immunotherapy. Biomaterials Science. 7(2). 547–559. 53 indexed citations
13.
Noto, Michael J., Kyle W. Becker, Kelli L. Boyd, Ann Marie Schmidt, & Eric P. Skaar. (2017). RAGE-Mediated Suppression of Interleukin-10 Results in Enhanced Mortality in a Murine Model of Acinetobacter baumannii Sepsis. Infection and Immunity. 85(3). 24 indexed citations
14.
Becker, Kyle W. & Eric P. Skaar. (2014). Metal limitation and toxicity at the interface between host and pathogen. FEMS Microbiology Reviews. 38(6). 1235–1249. 183 indexed citations
15.
Moore, Jessica L., Kyle W. Becker, Joshua J. Nicklay, et al.. (2013). Imaging mass spectrometry for assessing temporal proteomics: Analysis of calprotectin in Acinetobacter baumannii pulmonary infection. PROTEOMICS. 14(7-8). 820–828. 43 indexed citations
16.
Hood, M. Indriati, Kyle W. Becker, Christelle M. Roux, Paul M. Dunman, & Eric P. Skaar. (2013). Genetic Determinants of Intrinsic Colistin Tolerance in Acinetobacter baumannii. Infection and Immunity. 82(1). 469–469. 2 indexed citations
17.
Hood, M. Indriati, Kyle W. Becker, Christelle M. Roux, Paul M. Dunman, & Eric P. Skaar. (2012). Genetic Determinants of Intrinsic Colistin Tolerance in Acinetobacter baumannii. Infection and Immunity. 81(2). 542–551. 62 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026